Obermatt
See Similar Stocks →

DiaSorin

MIL:DIA · IT0003492391
Health Care Equipment & SuppliesLarge

360

34
EV / EBIT49
Price / Owner Earnings44
Owner Earnings Yield68
Dividend Yield71
Price/Sales53
EV / Gross Profit31
Price/Book66
Return on Capital63
Cash Return on Capital62
Return on Equity53
EBIT Margin92
Gross Profitability33
Cash Conversion79
Accruals56
Owner Earnings Margin88
Sales growth32
Profit Growth69
Long-Term EPS Growth49
Owner Earnings Growth28
Reinvestment15
Price momentum30
Debt load47
Refinancing24
Debt Payback27
Liquidity67
Analyst ratings5
Opinion Changes33
Price Target Upside16
Market mood19
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

DiaSorin clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryItaly
IndustryHealth Care Equipment & Supplies
SizeLarge
TypePublic Company
ExchangeBIT
Employees2,118
Websiteint.diasorin.com/en
ISINIT0003492391
Last UpdateApr 2, 2026
Indices
MIB (Italy)
Themes
Infectious DiseasesBiomedical EngineeringHealth DiagnosticsGeneticsImmunologyEndocrinologyChronic DiseasesOncologyBiotechnology

Description

DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits. Business Segments The company operates through Immunodiagnostics, Molecular Diagnostics, and Licensed Technologies se…

Analysis

Quality compounder

DiaSorin S.p.A. earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess.

On valuation, the picture is fair. The owner-earnings multiple stands at 20.7×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 7% a year, against analyst forecasts of 9%. The price, in other words, assumes less than the experts do.

Growth is tepid; the safety picture is adequate. The company scores 8/20 on our value-creation score: creating some value. Analyst sentiment is cautious.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
12
2023202420252026

All-time high

80

Jan 2025

All-time low

6

Jan 2024

Average rank

46

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
53
26
27
27
Price/Earnings
44
34
33
31
Price/Book
66
40
37
37
Dividend Yield
71
46
39
37
Value (overall)
75
35
23
34

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare DiaSorin with its peers
Roche
VTX:ROG
84
CountrySwitzerland
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
Immunocore
NSQ:IMCR
40
CountryUK
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Transgene
PAR:TNG
15
CountryFrance
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
bioMerieux
PAR:BIM
72
CountryFrance
IndustryHealth Care Equipment & Supplies
SizeLarge
Full Stock Analysis →
Sol-Gel Technologies
NAQ:SLGL
36
CountryIsrael
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Stratec
GER:SBS
36
CountryGermany
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →